Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-02-13

Clinical Trial Update: A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of MIL62 for systemic lupus erythematosus is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MIL62

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: NOT_YET_RECRUITING